Sep 3 2009
Champions Biotechnology, Inc. (OTC Bulletin Board: CSBR), a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, has established yet another agreement with a large biotechnology company for the evaluation of a novel oncology therapeutic in Champions' Biomerk Tumorgraft(TM) platform.
By maintaining the fundamental genotypic features of the original human tumor along with the stromal components, the Biomerk Tumorgraft preclinical platform enables identification of the most promising development path for a compound in terms of indication, drug combination, and target patient population. The platform also has the potential to identify gene pathways of response and resistance as well as prognostic molecular biomarkers.
"We are excited to continue the growth of our impressive client base and begin working with one of the most respected global leaders in the discovery and development of novel therapies," said Doug Burkett, Ph.D., President of Champions Biotechnology, Inc. "Studies suggest that evaluation of oncology compounds through our Biomerk Tumorgraft platform will lead to more successful and efficient clinical development. The value-added by an optimally targeted, more efficient clinical path can result in cost savings, improved clinical and commercial success and significantly more years of patent life following commercialization."
Source: http://championsbiotechnology.com
Early genomic profiling improves cancer treatment outcomes